Back

ReposiTrak revenue reaches $23.3 million as fiscal 2026 margin expands to 33.7%

Verifying
  • ReposiTrak reported fiscal 2026 results with higher profit and lower operating expenses.
  • $23.3 million revenue rose 3%, while diluted EPS increased 13% to $0.39.
  • FDA extended Traceability Rule 204 compliance to July 20, 2028.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.